EPI Übernahme - Wir halten zusammen
This legislation would increase access to blood-based screening tests to allow people to understand if they are at risk of colon cancer before scheduling a more invasive colonoscopy. Currently, the lack of authorization for reimbursement from Medicare is preventing people from accessing all screening options for colorectal cancer. This bill would address this problem by placing all Food and Drug Administration (FDA)-approved blood-based screening tests on equal footing with other screening methods and authorize reimbursement from the Centers for Medicare & Medicaid Services (CMS).
Colorectal cancer is largely preventable, yet still remains the third leading cause of cancer-related deaths in the United States, Wicker said. This legislation would increase screening options for Medicare beneficiaries, helping to improve detection among an otherwise unscreened population.
Colon cancer is one of the most common diseases in New Mexico, but is actually preventable and treatable when it is found early. Improving colon cancer screening rates helps with early detection and can save lives, Heinrich said. This bipartisan bill would make it easier for people to access all screening options for colon cancer, including non-evasive blood-based screening tests.
Colon cancer disproportionately impacts communities of color, but we know it is more treatable when detected early. Thats why improving access to colon cancer screenings is so critical, Padilla said. Simply put, the Colorectal Cancer Detection Act will save lives by making it easier to access colon cancer screenings for Californians and everyone across the country.
The Colorectal Cancer Detection Act seeks to authorize blood-based screening tests for CMS reimbursement and remove this potential barrier to screening. By increasing access to, and participation in, screening programs, thousands of colorectal cancers which may otherwise go undetected could be found, and thus save lives.
Optionen
| Boardmail an "HAL2016" |
Wertpapier: Epigenomics AG |
der senat hat 100 mitglieder.
senator wicker ist republikaner, die beiden anderen demokraten.
die chancen auf eine erstattung steigen.
alter Wein in neuen Schläuchen
gab es von den beiden schon Mar 03 2015
U.S. Sens. Sherrod Brown (D-OH), Roger Wicker (R-MS)
Because there is no way of knowing whether a polyp will be removed during a screening colonoscopy in advance, Medicare beneficiaries do not know whether or not their screening colonoscopy will be fully covered until after the procedure is over. This potential cost could lead to Medicare beneficiaries electing to forgo this important preventive screening, even though colorectal cancer screening is promoted as a service without cost-sharing under Medicare. Under the Affordable Care Act, private insurers cannot impose cost-sharing for a screening that leads to polyp removal, but Medicare can charge fees if a polyp is removed. The Removing Barriers to Colorectal Cancer Screening Act would correct this discrepancy by waiving cost-sharing under Medicare for preventive colonoscopies, even if a polyp or tissue is removed. U.S. Rep. Donald M. Payne, Jr. (D-NJ-10) introduced a companion bill today in the House of Representatives.
https://www.wicker.senate.gov/public/index.cfm/...3-BC84-F31CE173F8D8
warum haben diese drei
die vorlage eingebracht. in den senat.
ein republikaner und zwei demokraten.
aus langweile oder weil sie nicht die hellsten lichter auf der torte sind ???
Und jährlich grüßt das Murmeltier.
Ich weiß ganz genau, dass dann 2023 die gleiche Diskussion erneut entsteht. Wie bereits in den Jahren davor.
es geht nicht um den herbst 2022.
das gesetz oder die gesetzesvorlage wurde j e t z t eingebracht.
in der HV wurde von dem legislativen weg berichtet.
nach dem repäsentantenhaus (im märz) wurden nun auch im senat
die voraussetzungen für eine weitere bearbeitung in beiden häusern geschaffen.
Wenn nix da ist, hofft man eben alles Jahre wieder auf die Gesetzesinitiative…
Wünsche euch viel Glück. Ihr werdet es brauchen. Hoffentlich macht epi nicht wieder den ersten Rang in der Kurs Performance…
Optionen
| Boardmail an "nwolf" |
Wertpapier: Epigenomics AG |
Optionen
| Boardmail an "nwolf" |
Wertpapier: Epigenomics AG |